Special Issue

Liquid Biopsy and Precision Oncology

Message from the Guest Editors

Liquid biopsy, the analysis of tumors using biomarkers circulating in body fluids, has emerged as a promising non-invasive tool for cancer management. Much attention was paid to circulating tumor cells (CTCs) first. followed by circulating tumor DNA (ctDNA), extracellular vesicles and other tumor-derived products. The growing demand for predictive biomarkers for targeted therapy and the availability of advanced and highly sensitive technologies have brought ctDNA analysis into clinical practice. However, the liquid biopsy is not restricted to molecular profiling but also allows information on tumor biology to be gained through the real-time assessment of the evolving landscape of cancer. Therefore, it is only right to integrate all the information about the different products released into fluids by tumors in order to monitor cancer progression. This Special Issue of *Diagnostics* will cover all the different aspects of liquid biopsy, from the pre-analytical phase to clinical impact, in order to assemble a huge corpus of cancer precision medicine knowledge.

Guest Editors

Dr. Chiara Nicolazzo

Cancer Liquid Biopsy Unit, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy

Prof. Dr. Paola Gazzaniga

Chief Liquid Biopsy Unit, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy

Deadline for manuscript submissions

closed (15 October 2022)



Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



mdpi.com/si/97229

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

mdpi.com/journal/diagnostics





Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

